reviewTop 1% cited
The biology and treatment of EML4-ALK non-small cell lung cancer
European Journal of Cancer · 2010 · Vol. 46(10) · pp. 1773–1780
Takaaki Sasaki(Dana-Farber Cancer Institute)Scott J. Rodig(Brigham and Women's Hospital)Lucian R. Chirieac(Brigham and Women's Hospital)Pasi A. Jänne✉(Harvard University)
Lung Cancer Treatments and MutationsLung Cancer Research StudiesNeuroendocrine Tumor Research AdvancesAnaplastic lymphoma kinaseLung cancerCancer researchMedicineCrizotinibBiologyKinaseTargeted therapyIn vivoAnaplastic large-cell lymphoma
MeSH terms
Anaplastic Lymphoma KinaseAntineoplastic AgentsCarcinoma, Non-Small-Cell LungEnzyme InhibitorsHumansLung NeoplasmsMutationProtein-Tyrosine KinasesSmokingTranslocation, GeneticGene RearrangementOncogene Proteins, FusionIn Situ Hybridization, FluorescenceReverse Transcriptase Polymerase Chain ReactionReceptor Protein-Tyrosine Kinases
Funding
- National Institutes of Health
Citations
556
FWCI
40.89
field-weighted impact
References
44
Percentile
100%
vs. same field & year
Citations per year
References
The global burden of cancer: priorities for prevention
Carcinogenesis · 2009 · 1,076 citations
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>
Journal of Clinical Oncology · 2009 · 1,873 citations
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
JNCI Journal of the National Cancer Institute · 2005 · 2,385 citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
New England Journal of Medicine · 2009 · 8,201 citations
<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Clinical Cancer Research · 2008 · 975 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.